Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial - Cree, B AC; Bennett, J L; Kim, H J; N-MOmentum study investigators (Lancet, 2019)
(10206):